Jump Financial LLC Acquires 141,172 Shares of Intellia Therapeutics, Inc. $NTLA

Key Points

• Jump Financial LLC increased its stake in Intellia Therapeutics by 38.9%, acquiring an additional 141,172 shares, bringing its total holdings to 503,809 shares valued at approximately $3.58 million.
• Significant investor activity includes Voloridge Investment Management LLC increasing its holdings by 226.8% and Two Sigma Advisers LP growing theirs by 94.5% during the last quarter.
• Analysts have adjusted their price targets for Intellia Therapeutics, with Wells Fargo lowering its target from $50.00 to $45.00, while other firms have proposed targets ranging from $14.00 to $60.00.

Jump Financial LLC increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 38.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 503,809 shares of the company's stock after buying an additional 141,172 shares during the period. Jump Financial LLC owned about 0.49% of Intellia Therapeutics worth $3,582,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $25,000. Northwestern Mutual Wealth Management Co. lifted its stake in Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after purchasing an additional 1,655 shares during the last quarter. Harbour Investments Inc. lifted its stake in Intellia Therapeutics by 76.7% during the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after purchasing an additional 2,264 shares during the last quarter. Quantbot Technologies LP increased its position in Intellia Therapeutics by 846.4% during the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company's stock worth $47,000 after buying an additional 5,959 shares during the period. Finally, Virtus ETF Advisers LLC increased its position in Intellia Therapeutics by 47.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock worth $61,000 after buying an additional 1,692 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Trading Up 1.6%

NASDAQ NTLA traded up $0.18 during mid-day trading on Thursday, reaching $11.60. 3,756,477 shares of the company's stock traded hands, compared to its average volume of 4,584,764. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.76. The company has a fifty day simple moving average of $11.24 and a 200-day simple moving average of $9.57. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -2.47 and a beta of 2.31.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business's revenue was up 104.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.52) EPS. Equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NTLA shares. Canaccord Genuity Group reduced their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday, June 3rd. Wells Fargo & Company restated an "overweight" rating and issued a $45.00 price objective (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. Royal Bank Of Canada dropped their target price on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. HC Wainwright dropped their target price on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.05.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William J. Chase purchased 100,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were bought at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the purchase, the director owned 134,693 shares in the company, valued at $1,350,970.79. This represents a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 12,534 shares of company stock worth $153,837 over the last ninety days. 3.10% of the stock is owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.